Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- DSM and Crucell Announce PER.C6(R) Technology Milestone
- Leiden, The Netherlands/Parsippany, USA, 11 March 2008 - DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that another important milestone has been achieved with...
- Research articles 2008-03-11
- Crucell and DSM intensify collaboration and development of PER.C6(R) human cell line
- Sittard/Leiden, The Netherlands, February 8, 2007 - DSM Biologics, a business unit of DSM Pharmaceuticals, and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that they have further intensified their PER.C6® collaboration, by executing an agreement to expand the existing commercial relationship to include new...
- Research articles 2007-02-08
- DSM and Crucell Celebrate Opening of PERCIVIA PER.C6(R) Development Center in Cambridge, Mass.
- New facility exclusively dedicated to research and development of PER.C6® human cell line platform for licensees Parsippany, USA/Leiden, The Netherlands, November 8, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and technology partner DSM Biologics, a business unit...
- Research articles 2006-11-08
- DSM and Crucell celebrate opening of PERCIVIA PER.C6(R) Development Center
- New facility exclusively dedicated to research and development of PER.C6® human cell line platform for licensees Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and technology partner DSM Biologics, a business unit of DSM Pharmaceutical Products announced today the opening of the PERCIVIA PER.C6® Development Center,...
- Research articles 2006-11-08
- Crucell and DSM Announce PER.C6(R) Licensing Agreement with ZyStor Therapeutics
- Leiden/Sittard, The Netherlands, December 21, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6® research ...
- Research articles 2005-12-21
- Crucell and DSM Announce Second PER.C6(R) License Agreement with Ferring Pharmaceuticals
- Leiden/Sittard, The Netherlands, December 21, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and allied contract manufacturer DSM Biologics announced today that they have signed a second ...
- Research articles 2005-12-21
- Crucell and DSM announce PER.C6 licensing agreement with Chiron; GlycoGenesys, Inc. conference call alert for August 22, 2005.
- M2 PRESSWIRE-16 August 2005-US Financial Network: Crucell and DSM announce PER.C6 licensing agreement with Chiron; GlycoGenesys, Inc. conference call alert for August 22, 2005C1994-2005 M2 COMMUNICATIONS LTD RDATE:16082005 City of Industry, CA - Biotechnology industry news provided by Financial News...
- Research articles 2005-08-16
- Pharma problems hurt results at European firms.(Custom Manufacturing)
- Problems in the custom manufacturing sector have hurt results at several major European firms, including Akzo Nobel, DSM, Lonza, and Rhodia. Most reported lower sales and profits for their pharma businesses in the latest quarter. "The agony in custom manufacturing continues, which does not come as...
- Research articles 2004-08-11
- The chemical industry in the Netherlands: a key sector struggles with economic slowdown.(The Netherlands Country Focus)
- Chemicals play a crucial role in the economy and industry of the Netherlands. The Dutch chemical industry ranks second in the world, after that of Belgium, in terms of the relative contribution of a country's chemical industry to GDP, the Netherlands' chemical industry association VNCI Leidschendam...
- Research articles 2003-11-26
- Delay in reopening of DSM glyoxylic acid plants.(News: Europe)(Brief Article)
- EUROPEAN consumers of the intermediate glyoxylic acid could encounter shortages of the product because of a delay in restarting DSM's two glyoxylic acid plants at Linz, Austria. A mid-August explosion at one of the units forced both to be taken off line. ...
- Research articles 2003-09-08
- An early start: Dow, DSM, Degussa, Helsinn and Clariant are all at it. Robert Winder shows how early phase alliances between fine chemicals companies and pharma customers can benefit all parties
- Speaking at Informex in February 2003, Andrew Liveris, president of Dow Chemical's performance chemicals business, suggested that custom manufacturers in the fine chemicals sector should start their alliances with pharmaceuticals customers earlier. Liveris' view seems to be reflected in the fine chemicals sector as a whole. Companies are forming alliances...
- Research articles 2003-06-02
- Slowdown in pharma sales lowers fiscal returns. (News: Europe).
- EUROPEAN CHEMICAL majors Clariant, Akzo Nobel and DSM saw revenues slip in 2002, and, for Clariant and Akzo Nobel, margins were hit hard by disappointing performances in their life sciences segments. Clariant posted a net loss of SFr 648 million ($473 million)...
- Research articles 2003-02-17
- DSM to acquire Roche's vitamins business? (Top of the Week).(DSM, Roche Holding Ltd.)(Brief Article)(Statistical Data Included)
- DSM is negotiating to acquire Roche's vitamins and fine chemicals business, according to a report last week in German newspaper Badische Zeitung. DSM and Roche declined to comment on the report. Roche announced plans earlier this year to divest the SF3.5-billion ($2.2 billion)/year vitamins...
- Research articles 2002-06-05
- SABIC acquires DSM petrochem
- Saudi Basic Industries SABIC, Riyadh, is paying [euro]2.25bn ($1.97bn) for Dutch company DSM's petrochemical assets. The move could precipitate a major round of restructuring in the European fine and speciality chemicals industry. It also puts the future of a joint venture with Sabic and Eni Chem in doubt, for the...
- Research articles 2002-04-15
- Custom manufacturers see growth in biopharmaceuticals: Fine chemicals companies are staking their claims in a biologics market that could be worth $2 billion in four years. (Focus 2002: Biopharmaceuticals & Fine Chemicals).(Industry Overview)(Statisti
- The biopharmaceutical market is large and growing fast, but manufacturing capacity is limited. New biologics plants are a very costly proposition, and until a few years ago, the development of outsourced capacity was hindered by regulations. Increasingly, however, fine chemicals players accustomed to serving the pharmaceutical...
- Research articles 2002-03-11
- Leveraging Innovation: Specialties Firms Reembrace R&D. (Cover Story).(Cabot Microelectronics key example)(Statistical Data Included)
- To INVENT A BRILLIANT NEW product and grow it into a big, money-spinning business, has been the classic inspiration for specialty chemicals makers. The bad news is that much of the sector has fallen short of that vision during the past decade, and 2001 results are almost...
- Research articles 2001-12-19
- Nylon's Allure Slips; Producers Try a Low-Fiber Diet.(Statistical Data Included)
- Nylon, an industry cornerstone, is coming to grips with middle age. Economic crises in Asia and Eastern Europe have sapped growth and battered prices, demonstrating that nylon is not immune to harsh industry cycles. Producers are cutting costs and shifting from weaker end markets, including apparel,...
- Research articles 1999-10-06
- Changes ahead for PE technologies.(polyethylene)
- Innovations in catalyst technologies have broadened the highly competitive polyethylene PE licensing business. Chemical firms such as Montell Polyolefins, BP Chemicals, Nova Chemicals, DSM and BASF have challenged Union Carbide's leadership in PE licensing by signing licensing deals for their gas-phase and solution-phase technologies. Polymer and resin manufacturers could use...
- Research articles 1996-07-17
Additional Resources
- DSM becomes Royal DSM. (Nitrogen Industry News).(brief history and plans of coal mining company)(Brief Article)
- On the 100th anniversary of its foundation DSM has become Royal DSM. In 1902 the Dutch government founded Dutch State Mines later to become DSM as a state-owned coal-mining company. As DSM expanded its coal mining and processing activities, production of the by-product coke oven gas...
- Research articles 2002-07-01
- DSM to build DSM China campus.(NEWSDESK: Expansion)(Royal Dsm N.V.)(Brief article)
- On January 30th, 2007 Royal DSM N.V. announces that it has decided to build a DSM China Campus in Zhangjiang Hi-Tech Park, Pudong New Area of Shanghai. The China Campus will comprise both all Shanghai offices of the DSM China Ltd. Holding and several business groups and...
- Research articles 2007-02-26
- << Previous
- page 1 of 1
- Next >>
